Anecortave

Anecortave
Clinical data
Pregnancy; category	?;
Routes of; administration	intravitreal depot injection
ATC code	S01XA16 (WHO) ;
Legal status
Legal status	Schedule 4 (Aust);
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
	IUPAC name [2-[(8R,10S,13S,14R,17R)-; 17-hydroxy-10,13-dimethyl-3-oxo-; 2,6,7,8,12,14,15,16-octahydro-; 1H-cyclopenta[a]phenanthren-17-yl]-; 2-oxo-ethyl] acetate;
CAS Number	7753-60-8;
PubChem CID	111332;
DrugBank	?;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H30O5
Molar mass	386.48

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Anecortave (rINN) (Template:PronEng) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It is marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.

External links

Template:Pharma-stub

Clinical data
Pregnancy category	?
Routes of administration	intravitreal depot injection
ATC code	S01XA16 (WHO)
Legal status
Legal status	Schedule 4 (Aust)
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
IUPAC name [2-[(8R,10S,13S,14R,17R)- 17-hydroxy-10,13-dimethyl-3-oxo- 2,6,7,8,12,14,15,16-octahydro- 1H-cyclopenta[a]phenanthren-17-yl]- 2-oxo-ethyl] acetate
CAS Number	7753-60-8
PubChem CID	111332
DrugBank	?
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₃₀O₅
Molar mass	386.48

Anecortave

External links

Navigation menu